Evidence map›Paper›PMID 40735701›Full record

ArticleMaterials today. Bio2025

Analysis of the therapeutic effect and potential mechanism of Fe

Xiaoming Zhao, Chenfei Kong, Xue Xia, Kelin Zhao, Miao Hao, Yiyao Gao, Yuqian Wang, Zhiying Chen, Jinlan Jiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaoming ZhaoScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Chenfei KongScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Xue XiaDepartment of Rheumatology and Immunology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Kelin ZhaoDepartment of Rheumatology and Immunology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Miao HaoScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Yiyao GaoScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Yuqian WangScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Zhiying ChenDepartment of Respiratory Medicine, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Jinlan JiangScientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary fibrosis (PF) is a chronic lung disease characterized by progressive fibrosis and scar tissue formation, often leading to respiratory failure. Current treatments are limited to alleviating symptoms and slowing disease progression. Mesenchymal stem cells (MSC) can be applied to treat PF owing to their anti-inflammatory, immunomodulatory, tissue repair, and vascular regeneration properties. However, the short pulmonary retention time of intravenously injected MSC limits therapeutic efficacy. We combined MSC with Fe

Indexed as

Lung reparationMagnetite nanoparticlesMesenchymal stem cellsPolydopaminePulmonary fibrosis

Identifiers

PMID40735701
PMCPMC12305185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.